PTC Therapeutics (NASDAQ: PTCT) net income
PTC Therapeutics reported a net profit of $682.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $363.3m. Its net margin was 39.4%. Earnings per share were $8.58.
Fiscal 2025 is the highest of the 10 fiscal years on record for PTC Therapeutics. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $682.6m | — | 39.4% | $8.58 |
| 2024 | −$363.3m | — | −45.0% | −$4.73 |
| 2023 | −$626.6m | — | −66.8% | −$8.37 |
| 2022 | −$559.0m | — | −80.0% | −$7.79 |
| 2021 | −$523.9m | — | −97.3% | −$7.43 |
| 2020 | −$438.2m | — | −115.1% | −$6.64 |
| 2019 | −$251.6m | — | −82.0% | −$4.27 |
| 2018 | −$128.1m | — | −48.4% | −$2.75 |
| 2017 | −$79.0m | — | −40.6% | −$2.02 |
| 2016 | −$142.1m | — | −171.8% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
PTC Therapeutics net income compared with its sector
By net income for its latest fiscal year, PTC Therapeutics ranks 54th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of PTC Therapeutics, 39.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 52nd | DaVita | $746.8m | 5.5% |
| 53rd | Zimmer Biomet | $705.1m | 8.6% |
| 54th | PTC Therapeutics | $682.6m | 39.4% |
| 55th | Waters | $642.6m | 20.3% |
| 56th | Encompass Health | $566.2m | 9.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of PTC Therapeutics
- How much did PTC Therapeutics earn in fiscal 2025?
- PTC Therapeutics reported a net profit of $682.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $363.3m.
- What are the earnings per share of PTC Therapeutics?
- They were $8.58 in fiscal 2025, compared with −$4.73 in fiscal 2024.
- What is the net margin of PTC Therapeutics?
- In fiscal 2025 its net profit was 39.4% of its revenue.
- What was the most profitable year for PTC Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $682.6m.
- Where does PTC Therapeutics rank in its sector by net income?
- It ranks 54th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for PTC Therapeutics come from?
- From the annual report (Form 10-K) that PTC Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that PTC Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on PTC Therapeutics: the PTC Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.